| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Renal Division, Department of Medicine [S. A., B. K., W. G., M. D., G. W., V. P. S.] and Department of Pathology [I. E. S.], Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215
The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in patients with VHL disease and in the majority of patients with sporadic clear cell renal carcinoma (RCC). Overexpression of transforming growth factor (TGF) ß1 has been observed in patients with several cancers, including RCCs, with serum and urine levels correlating inversely with prognosis. We have demonstrated that the VHL tumor suppressor gene product represses TGF-ß1 mRNA and protein levels (
3–4-fold) in 786-O RCC cells by decreasing the TGF-ß1 mRNA half-life. Exogenously added TGF-ß1 did not suppress the growth of 786-O cells in vitro, nor did the addition of neutralizing antibody (Ab) against TGF-ß have any effect. Indeed, 786-O cells were found to express no TGF-ß type II receptor protein, thus allowing them to escape from the negative growth control of TGF-ß1. In contrast to the in vitro data, neutralizing Ab to TGF-ß inhibited tumorigenesis and, in some cases, regressed established 786-O tumors in athymic mice. Immunohistochemistry for von Willebrand’s factor revealed a 3–4-fold lower tumor microvessel count in the mice treated with TGF-ß Ab compared to controls, suggesting that the Ab was inhibiting angiogenesis. Our findings indicate that TGF-ß1 is a novel target for the VHL tumor suppressor and that antagonizing its paracrine action may provide novel avenues for treatment of RCCs as well as other tumors that secrete TGF-ß1.
This article has been cited by other articles:
|
|
 |
|
  Z. S. Morris and A. I. McClatchey Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma PNAS, June 16, 2009; 106(24): 9767 - 9772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M. E. MERCADO-PIMENTEL, R. B. RUNYAN, D. G. BESSELSEN, X. ZHANG, H.-K. CHEUNG, et al. An Orally Active Small Molecule TGF-{beta} Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer Anticancer Res, June 1, 2009; 29(6): 2099 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Wacker, M. Sachs, K. Knaup, M. Wiesener, J. Weiske, O. Huber, Z. Akcetin, and J. Behrens Key Role for Activin B in Cellular Transformation after Loss of the von Hippel-Lindau Tumor Suppressor Mol. Cell. Biol., April 1, 2009; 29(7): 1707 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xie, V. A. Valera, M. J. Merino, A. M. Amato, S. Signoretti, W. M. Linehan, V. P. Sukhatme, and P. Seth LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer Mol. Cancer Ther., March 1, 2009; 8(3): 626 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Teicher, J. M Yingling, and J. M McPherson TGF{beta} Blockade as Anticancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Teicher Transforming Growth Factor-{beta} and the Immune Response to Malignant Disease Clin. Cancer Res., November 1, 2007; 13(21): 6247 - 6251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Laping, J. I. Everitt, K. S. Frazier, M. Burgert, M. J. Portis, C. Cadacio, L. I. Gold, and C. L. Walker Tumor-Specific Efficacy of Transforming Growth Factor-{beta}RI Inhibition in Eker Rats Clin. Cancer Res., May 15, 2007; 13(10): 3087 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Kaelin Jr. The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 680s - 684s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Evans, R. C. Russell, O. Roche, T. N. Burry, J. E. Fish, V. W. K. Chow, W. Y. Kim, A. Saravanan, M. A. Maynard, M. L. Gervais, et al. VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail Mol. Cell. Biol., January 1, 2007; 27(1): 157 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iliopoulos Molecular Biology of Renal Cell Cancer and the Identification of Therapeutic Targets J. Clin. Oncol., December 10, 2006; 24(35): 5593 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ge, V. Rajeev, P. Ray, E. Lattime, S. Rittling, S. Medicherla, A. Protter, A. Murphy, J. Chakravarty, S. Dugar, et al. Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-{beta} Type I Receptor Kinase In vivo. Clin. Cancer Res., July 15, 2006; 12(14): 4315 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Talon, V. Lindner, C. Sourbier, E. Schordan, S. Rothhut, M. Barthelmebs, H. Lang, J.-J. Helwig, and T. Massfelder Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo Carcinogenesis, January 1, 2006; 27(1): 73 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Hainsworth, J. A. Sosman, D. R. Spigel, D. L. Edwards, C. Baughman, and A. Greco Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib J. Clin. Oncol., November 1, 2005; 23(31): 7889 - 7896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Muraoka-Cook, N. Dumont, and C. L. Arteaga Dual Role of Transforming Growth Factor ss in Mammary Tumorigenesis and Metastatic Progression Clin. Cancer Res., January 15, 2005; 11(2): 937s - 943s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Zhou, H. Wang, R. L. Foy, J. J. Ross, and H. T. Cohen Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and Is VHL Mutation Dependent Cancer Res., February 15, 2004; 64(4): 1278 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Massfelder, H. Lang, E. Schordan, V. Lindner, S. Rothhut, S. Welsch, P. Simon-Assmann, M. Barthelmebs, D. Jacqmin, and J.-J. Helwig Parathyroid Hormone-Related Protein Is an Essential Growth Factor for Human Clear Cell Renal Carcinoma and a Target for the von Hippel-Lindau Tumor Suppressor Gene Cancer Res., January 1, 2004; 64(1): 180 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Kaelin Jr. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2703 - 2711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-M. Miao, W. Lin Seng, M. Duquette, P. Lawler, C. Laus, and J. Lawler Thrombospondin-1 Type 1 Repeat Recombinant Proteins Inhibit Tumor Growth through Transforming Growth Factor-{beta}-dependent and -independent Mechanisms Cancer Res., November 1, 2001; 61(21): 7830 - 7839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takahashi, A. Haba, F. Matsuno, and B. K. Seon Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide Cancer Res., November 1, 2001; 61(21): 7846 - 7854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lawler, W.-M. Miao, M. Duquette, N. Bouck, R. T. Bronson, and R. O. Hynes Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice Am. J. Pathol., November 1, 2001; 159(5): 1949 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. KARUMANCHI, L. JIANG, B. KNEBELMANN, A. K. STUART-TILLEY, S. L. ALPER, and V. P. SUKHATME VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells Physiol Genomics, April 2, 2001; 5(3): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Shiao, J. H. Resau, K. Nagashima, L. M. Anderson, and G. Ramakrishna The von Hippel-Lindau Tumor Suppressor Targets to Mitochondria Cancer Res., June 1, 2000; 60(11): 2816 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Harris von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy Oncologist, April 1, 2000; 5(90001): 32 - 36. [Abstract] [Full Text]
|
|
|
|
|
|
M. Los, S. Zeamari, J. A. Foekens, M. F. B. G. Gebbink, and E. E. Voest Regulation of the Urokinase-type Plasminogen Activator System by the von Hippel-Lindau Tumor Suppressor Gene Cancer Res., September 1, 1999; 59(17): 4440 - 4445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Ivanova, S. V. Ivanov, A. Danilkovitch-Miagkova, and M. I. Lerman Regulation of STRA13 by the von Hippel-Lindau Tumor Suppressor Protein, Hypoxia, and the UBC9/Ubiquitin Proteasome Degradation Pathway J. Biol. Chem., April 27, 2001; 276(18): 15306 - 15315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Devarajan, M. De Leon, F. Talasazan, A. R. Schoenfeld, E. J. Davidowitz, and R. D. Burk The von Hippel-Lindau Gene Product Inhibits Renal Cell Apoptosis via Bcl-2-dependent Pathways J. Biol. Chem., October 26, 2001; 276(44): 40599 - 40605. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
